| |
|
|
KEYNOTE SPEAKER:
Kenneth I. Kaitin, Ph.D.
Director, Tufts Center for the Study of Drug Development
Associate Professor of Medicine, Tufts University School of Medicine
Tufts University |
Dr. Kaitin is Director of the Tufts Center for the Study of Drug Development, an academic drug policy research group providing strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of the drug development process. He is also Associate Professor of Medicine at Tufts University School of Medicine, and he serves on the faculty of the European College of Pharmaceutical Medicine at the University of Basel.
Dr. Kaitin conducts research, lectures, and writes on pharmaceutical development, regulation, and public policy. He has written extensively on factors that contribute to the slow pace and high cost of pharmaceutical R&D and the impact of regulatory and legislative initiatives to speed new drug development and review. Dr. Kaitin has provided public testimony before the U.S. Congress in hearings on pharmaceutical innovation and FDA reform, and he has worked closely with the U.S. Council on Competitiveness. He is on the Board of Directors of the New England Institute for Health Care Research and Innovation, and he served on the Center for Strategic and International Studies’ bioterrorism task force, “National Strategy for Anti-Biothreat Vaccines, Therapeutics, and Diagnostics.” Dr. Kaitin is a former President of the Drug Information Association (1997-98) and Editor-in-Chief of the Drug Information Journal (2002-04). He currently serves on the editorial boards of the American Journal of Therapeutics, Clinical Research and Regulatory Affairs, Drug Information Journal, Drug Discovery and Development, and the Food and Drug Letter.
Dr. Kaitin received a B.S. from Cornell University and an M.S. and Ph.D. in pharmacology from the University of Rochester.
|
|
